Floatz logo

Darleukin

Advanced Solid Tumours

Philogen S.p.A.protein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Advanced Solid Tumours cohort.

Asset / SponsorPhaseRating
Ceralasertib
AstraZeneca
Phase 2BB
Senaparib
Impact Therapeutics, Inc.
Phase 1/2B
Cyclophosphamide
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Epirubicin
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B

View all 50 →

Same molecule, other indications

Darleukin is also rated in:

melanomaDormant
B
Indicative ·
56 / 100
View asset →
cutaneous melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic melanomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →